Skip to content
value.today

Pulse Therapeutics, Inc.

🇺🇸 St. Louis, Missouri, USABiotechnologyFounded 2008
Total raised
$11 M
4 rounds on record
Latest round
$6 M
Jan 2016
First round on record
Apr 2011
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pulse Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2016$6 MNo. 4$2 to $10 million

Pulse Therapeutics, Inc.: Raise no. 4, Jan 2016

Investors in this round

29 investors had bought by the notice of Jan 27, 2016: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $14 M offered; $8 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peggy Stohr · Executive Officer
  • Sean Morris · Executive Officer, Director
  • Eric Moessinger · Director
  • Thomas Hillman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peggy S. Stohr, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 27, 2016. Read the notice at the SEC.

equitySEC
Dec 2013$1 MNo. 3Under $2 million

Pulse Therapeutics, Inc.: Raise no. 3, Dec 2013

Investors in this round

3 investors had bought by the notice of Feb 6, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Francis M. Creighton · Executive Officer, Director
  • Peggy A. Stohr · Executive Officer
  • Sean A. Morris · Executive Officer
  • Bevil J. Hogg · Director
  • Eric A. Gulve · Director
  • Stephen A. Wexler · Director
  • Thomas J. Hillman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sean Morris, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 6, 2014. Read the notice at the SEC.

equitySEC
Dec 2011$3 MNo. 2$2 to $10 million

Pulse Therapeutics, Inc.: Raise no. 2, Dec 2011

Investors in this round

4 investors had bought by the notice of Dec 30, 2011: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Francis M. Creighton · Executive Officer, Director
  • James C. Wachtman · Executive Officer
  • Peggy A. Stohr · Executive Officer
  • Rogers A. Ritter · Executive Officer
  • Bevil J. Hogg · Director
  • Daniel J. Broderick · Director
  • Stephen A. Wexler · Director
  • Thomas J. Hillman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James C. Wachtman, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 30, 2011. Read the notice at the SEC.

equitySEC
Apr 2011$2 MNo. 1Under $2 million

Pulse Therapeutics, Inc.: Raise no. 1, Apr 2011

Investors in this round

8 investors had bought by the notice of Aug 1, 2011: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amy L. Boyet · Executive Officer
  • Francis M. Creighton · Executive Officer, Director
  • Rogers M. Ritter · Executive Officer
  • Bevil J. Hogg · Director
  • Daniel J. Broderick · Director
  • Stephen A. Wexler · Director
  • Thomas J. Hillman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Amy L. Boyet, Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 1, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pulse Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2016).

    SEC Form D · Jan 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2016

That is all the official record says: Pulse Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pulse Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 29 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pulse Therapeutics, Inc.
NameRoleNamed in
Peggy StohrExecutive officerJan 2016
Sean MorrisExecutive officerJan 2016
Francis M. CreightonExecutive officerFeb 2014
Peggy A. StohrExecutive officerFeb 2014
Sean A. MorrisExecutive officerFeb 2014
James C. WachtmanExecutive officerDec 2011
Rogers A. RitterExecutive officerDec 2011
Amy L. BoyetExecutive officerAug 2011
Rogers M. RitterExecutive officerAug 2011
Peter S. FinleyExecutive officerApr 2011
Eric MoessingerDirectorJan 2016
Sean MorrisDirectorJan 2016
Thomas HillmanDirectorJan 2016
Bevil J. HoggDirectorFeb 2014
Eric A. GulveDirectorFeb 2014
Francis M. CreightonDirectorFeb 2014
Stephen A. WexlerDirectorFeb 2014
Thomas J. HillmanDirectorFeb 2014
Daniel J. BroderickDirectorDec 2011